Juno Therapeutics Inc (NASDAQ:JUNO) has been assigned a consensus recommendation of “Hold” from the twenty-one analysts that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, eighteen have given a hold rating and two have assigned a buy rating to the company. The average 1-year target price among analysts that have covered the stock in the last year is $57.93.
A number of brokerages recently weighed in on JUNO. BidaskClub cut Juno Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, February 27th. Leerink Swann cut Juno Therapeutics from an “outperform” rating to a “market perform” rating and lifted their price target for the stock from $56.00 to $87.00 in a research note on Tuesday, January 23rd. Alex. Brown cut Juno Therapeutics from an “outperform” rating to a “hold” rating in a research note on Tuesday, January 23rd. SunTrust Banks reaffirmed a “hold” rating on shares of Juno Therapeutics in a research note on Monday, January 22nd. Finally, Barclays cut Juno Therapeutics from an “overweight” rating to an “equal weight” rating and lifted their target price for the company from $55.00 to $87.00 in a research note on Wednesday, January 24th.
Shares of JUNO opened at $86.96 on Wednesday. Juno Therapeutics has a 1-year low of $19.62 and a 1-year high of $87.01. The company has a quick ratio of 4.77, a current ratio of 3.61 and a debt-to-equity ratio of 0.01.
In related news, EVP Robert Azelby sold 4,167 shares of the business’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $85.78, for a total value of $357,445.26. Following the completion of the sale, the executive vice president now owns 96,471 shares of the company’s stock, valued at approximately $8,275,282.38. The sale was disclosed in a document filed with the SEC, which is available at this link. In the last three months, insiders sold 114,360 shares of company stock valued at $9,857,003. 15.08% of the stock is currently owned by company insiders.
Several hedge funds and other institutional investors have recently made changes to their positions in JUNO. Janus Henderson Group PLC bought a new stake in shares of Juno Therapeutics in the 3rd quarter valued at approximately $37,351,000. BlackRock Inc. grew its stake in shares of Juno Therapeutics by 6.6% in the 4th quarter. BlackRock Inc. now owns 4,834,370 shares of the biopharmaceutical company’s stock valued at $220,981,000 after buying an additional 299,586 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Juno Therapeutics by 108.5% in the 3rd quarter. Dimensional Fund Advisors LP now owns 392,974 shares of the biopharmaceutical company’s stock valued at $17,628,000 after buying an additional 204,493 shares in the last quarter. ARK Investment Management LLC grew its stake in shares of Juno Therapeutics by 31.0% in the 4th quarter. ARK Investment Management LLC now owns 682,495 shares of the biopharmaceutical company’s stock valued at $31,197,000 after buying an additional 161,380 shares in the last quarter. Finally, Amundi Pioneer Asset Management Inc. bought a new stake in shares of Juno Therapeutics in the 4th quarter valued at approximately $6,276,000. 70.19% of the stock is owned by institutional investors and hedge funds.
WARNING: This article was first posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this article on another publication, it was stolen and reposted in violation of US & international copyright and trademark laws. The original version of this article can be accessed at https://www.thelincolnianonline.com/2018/04/18/juno-therapeutics-inc-juno-receives-consensus-recommendation-of-hold-from-brokerages.html.
About Juno Therapeutics
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Receive News & Ratings for Juno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.